decisionhealth Newsletters, Part B News - 2018 Issue 4 (April)
Next-generation genetic cancer test gets NCD; for advanced cancer patients only
Subscribe or sign in to view the full article.
Article Overview
This article covers a CMS national coverage determination for next-generation sequencing laboratory tests in Medicare patients with advanced cancer. It focuses on who may qualify, how the coverage decision changed from proposal to final memo, and why professional groups are watching the policy closely. The piece is relevant to oncology, molecular diagnostics, laboratory compliance, and Medicare coverage policy.
Why This Topic Matters
The coverage decision affects access to advanced genetic testing for cancer patients and may influence laboratory workflows, oncology treatment planning, and payer policy interpretation. It also highlights how CMS, FDA status, and MAC discretion can shape coverage for molecular diagnostics.
Article Sections
-
CMS final coverage decision for NGS testing
Summarizes the CMS national coverage determination and the general scope of the Medicare policy for next-generation sequencing-based cancer testing.
-
Background on next-generation sequencing
Provides context on the testing technology, its general clinical role, and the broader diagnostics landscape.
-
Eligibility and coverage limits
Outlines the patient groups and broad coverage conditions discussed in the final decision memo, along with changes from the proposed policy.
-
Professional society response and implementation concerns
Describes the reaction from oncology stakeholders and the policy issues they identified regarding access, oversight, and local coverage variation.
What You Will Learn
- How CMS framed Medicare coverage for next-generation sequencing cancer testing
- Which broad patient categories were addressed in the final coverage decision
- What policy changes were noted between the draft and final CMS decision
- Why oncology groups are discussing access and implementation concerns
- How FDA status and contractor discretion factor into the coverage discussion
Who Should Read This
- Medical coders
- Oncology billing and reimbursement staff
- Clinical laboratory professionals
- Health information managers
- Payer policy analysts
- Oncologists and practice administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com